Drugs / NADRAVALEUCEL
NADRAVALEUCEL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03019666 | Oct 2017 → Aug 2022 | follicular lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, plasma cell myeloma +1 | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05296525 | Jul 2022 → Apr 2024 | non-Hodgkin lymphoma | Gamida Cell ltd | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NADRAVALEUCEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314693 ↗ |
| Known as | GDA-201 | “We also conducted a first-in-human phase 1 clinical trial testing adoptive transfer of NK cells expanded ex vivo with IL-15 and NAM (GDA-201) combined with monoclonal...” PMID 37467318 ↗ Jul 2023 |
| Known as | NAM-NK | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314693 ↗ |
| Modality | Cell therapy | “Cellular therapy with GDA-201 and rituximab was well tolerated and yielded an overall response rate of 74% in 19 patients with advanced NHL.” PMID 37467318 ↗ Jul 2023 |